Navigation Links
ROXRO PHARMA Marks 5th Year Of Cafe Scientifique Sponsorship
Date:4/16/2008

Thousands Have Participated in Wide Range of Scientific Discussions Since

ROXRO Organized Area's First Cafe Scientifique in 2004

MENLO PARK, Calif., April 16 /PRNewswire/ -- ROXRO PHARMA, Inc. today announced the continuation of its sponsorship of Cafe Scientifique Silicon Valley (http://www.cafescisv.org), an innovative concept that brings together scientists and the general public in a cafe environment for discussions on diverse scientific topics ranging from stem cells to global warming to genetically engineered foods.

"We are pleased to continue to support this innovative forum that brings cutting-edge and topical science to members of our community," said Roger Whiting, ROXRO PHARMA President and Chief Scientific Officer. "Cafe Scientifique has had remarkable success since we began the first cafe on the West Coast in 2004," he said.

The world's first Cafe Scientifique was held in 1998 in England and spawned a grassroots movement that has taken hold in hundreds of cities on every continent around the globe. The informal events are held in a variety of venues worldwide including bars, theaters, churches and other community gathering places.

Locally, ROXRO has been instrumental in organizing the participation of scientific and technology experts and in ensuring a very broad range of topics for discussion. Attendance at the monthly gatherings in Silicon Valley has risen steadily from about 50 initially to over 200 participants, requiring a move to larger quarters provided by SRI International at its headquarters in Menlo Park. "We are pleased to support Cafe Scientifique Silicon Valley and provide a space that accommodates the large number of participants while maintaining the informal cafe environment so essential to an open sharing of ideas and opinions," said Walter Moos, vice president of SRI's Bioscience Division.

"Cafe Scientifique is a place where anyone can come to learn about the latest ideas in science and technology in plain language," Whiting said. "We've had talks as diverse as gravitation and aging, saving whales, the chemistry of chocolate and nanotechnology. Our goal in organizing these monthly events is to make current scientific issues more accessible to the general public while making scientists more accountable to the public at large."

All Cafe Scientifique events are free and open to the public. Events are held at SRI's International Building at 333 Ravenswood Ave., Menlo Park. For more information on Cafe Scientifique Silicon Valley activities, go to http://www.cafescisv.org.

ABOUT ROXRO PHARMACEUTICALS

ROXRO PHARMA, Inc., of Menlo Park, is a privately owned specialty pharmaceutical company focused on the treatment of pain. Founded in 1999, Roxro in-licenses promising drug candidates for rapid development in acute pain conditions. The company's highly experienced management team engages a global network of experts to conduct pre-clinical and clinical studies and to manufacture drug products. This year Roxro plans to submit an application to the U.S. Food and Drug Administration seeking approval to market its lead compound, ROX-888, for the treatment of moderate-to-severe post-operative pain. For more information on Roxro, go to http://www.roxropharma.com.


'/>"/>
SOURCE ROXRO PHARMA, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Worldwide Pharmaceutical Industry Launches Global Health Progress Initiative to Expand Efforts to Improve Health in Developing Countries
2. Brandes Proposes 130 yen per Share Dividend and 10 Million Share Buyback Program for Ono Pharmaceutical Annual Meeting
3. AWWA Urges Science-Based Approach in Addressing Pharmaceutical Compounds in Water
4. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
7. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
8. Qforma Unveils Managed Care Optimization Solution for Pharma Marketing Executives
9. U.S. Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination
10. ApothecaryRx Provides Exit Strategy for Boomer Pharmacy Businesses; Sustains Service and Communication Structure of Community Pharmacies to Improve Drug Compliance, Reduce Drug Errors
11. NCPA Declares April 14 - 18 Protect Your Pharmacy Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: